Tonix Pharmaceuticals (Nasdaq: TNXP) Reports Positive Phase 3 Post Hoc Analyses and Recent FDA Approval of TONMYA for Fibromyalgia

Key Highlights for Investors

• FDA Approval and Launch: TONMYA^TM (cyclobenzaprine HCl sublingual tablets) was approved by the FDA as a treatment for fibromyalgia in adults on August 15, 2025, and launched in November 2025 — making it the first new prescription medicine approved for fibromyalgia in over 15 years.
• Positive Phase 3 Data: Post hoc analyses from pivotal Phase 3 trials (RESILIENT and RELIEF) demonstrate rapid, durable, and statistically significant pain relief, with a highly favorable benefit-risk profile compared to placebo.
• Investor Impact: TONMYA’s market exclusivity is expected to last until 2034/2035 due to robust patent protection, potentially providing a significant competitive advantage and substantial revenue opportunities.
• Additional Pipeline News: Tonix is advancing TONMYA for other CNS indications, including major depressive disorder and acute stress disorders, and moving forward with multiple pipeline assets, including treatments for Prader-Willi syndrome and Lyme disease prophylaxis.
• Important Safety and Prescribing Information: Detailed warnings, contraindications, and adverse reaction profiles were disclosed, which are critical for prescribers and may influence market uptake.

Detailed Report and Analysis

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced highly positive post hoc analyses of Phase 3 clinical data for its recently approved fibromyalgia drug, TONMYA^TM (cyclobenzaprine HCl sublingual tablets), at the 8th International Congress on Controversies in Fibromyalgia (March 9-10, 2026, Krakow, Poland). The company’s Chief Medical Officer, Dr. Gregory Sullivan, emphasized that TONMYA offers rapid and early-onset pain relief, a differentiated safety profile, and the potential to address significant unmet needs for the approximately 10 million adults with fibromyalgia in the U.S.

Clinical Data and Efficacy

• RESILIENT Trial: A 14-week, randomized, placebo-controlled Phase 3 study in 457 adults meeting the 2016 ACR criteria for fibromyalgia. TONMYA demonstrated:
  • Rapid reduction in pain observed as early as Day 2 of treatment with statistically significant pain relief maintained through Week 14.
  • Primary endpoint: Change from baseline to Week 14 in weekly average daily numeric rating scale (NRS) pain scores met with high statistical significance (p<0.001), and a least-squares mean treatment difference of -0.65.
  • All key secondary endpoints were statistically significant in favor of TONMYA.
  • Discontinuation due to adverse events was 6.1% with TONMYA versus 3.5% with placebo. Most common adverse events were oral hypoesthesia (23.8%) and abnormal product taste (11.7%), typically mild and transient.
• Pooled Analysis (RELIEF and RESILIENT Trials, n=959):
  • Number Needed to Treat (NNT): 7 (95% CI: 5–12) for achieving ≥30% pain reduction versus placebo at Week 14.
  • Number Needed to Harm (NNH): 26 (95% CI: 14–110) for discontinuation due to adverse event.
  • Likelihood to be Helped or Harmed (LHH): 3.7 — a nearly four-fold greater likelihood of clinical benefit than discontinuation for adverse events.
  • No new or unexpected safety signals were identified.

Commercial and Strategic Implications

• Market and Competitive Position:
  • TONMYA is the first FDA-approved fibromyalgia drug in over 15 years, entering a market with significant dissatisfaction among physicians and patients towards existing therapies.
  • With robust patent protection (multiple U.S. patents with exclusivity expected through 2034/2035), TONMYA is positioned as a novel, differentiated product, supporting sustained revenue and competitive advantage.
  • Tonix’s commercial infrastructure is already established for other CNS products (e.g., Zembrace^® SymTouch^® and Tosymra^®), which should facilitate rapid market adoption.
• Pipeline and Future Growth:
  • TONMYA is under evaluation for additional CNS indications (major depressive disorder, acute stress disorder).
  • Broader pipeline includes TNX-2900 for Prader-Willi syndrome (Phase 2 ready), TNX-4800 for Lyme disease prophylaxis, and TNX-1500 for kidney transplant rejection prevention.

Key Risks and Safety Information

• Contraindications and Warnings:
  • Contraindicated in patients with hypersensitivity to cyclobenzaprine, current/recent use of MAO inhibitors, during acute recovery from myocardial infarction, with specific cardiac conditions, or hyperthyroidism.
  • Potential for embryofetal toxicity; effective contraception required during treatment and two weeks after stopping medication. Pregnancy should be ruled out prior to initiation.
  • Risk of serotonin syndrome, especially with concomitant serotonergic agents; CNS depression possible, caution with alcohol and other CNS depressants.
  • Oral mucosal adverse reactions more frequent with TONMYA; patients should moisten mouth prior to dosing to mitigate risk.
  • Safety and efficacy not established in pediatric or geriatric populations (no patients ≥65 years in trials); not recommended for patients with moderate or severe hepatic impairment.
• Most Common Adverse Reactions (≥2% and higher than placebo):
  • Oral hypoesthesia, oral discomfort, abnormal product taste, somnolence, oral paresthesia, oral pain, fatigue, dry mouth, aphthous ulcer.

Investor and Shareholder Considerations

• TONMYA’s FDA approval and market launch represent a significant inflection point for Tonix Pharmaceuticals, opening a substantial revenue opportunity in an underserved market segment.
• The robust clinical data, rapid onset of action, and favorable benefit-risk profile provide a compelling value proposition and may drive strong adoption among prescribers and patients dissatisfied with current options.
• Patent protection and ongoing pipeline expansion enhance the company’s long-term growth prospects and could serve as meaningful catalysts for share price appreciation.
• Investors should closely monitor commercial uptake, future label expansions, and any post-marketing safety signals as key value drivers and potential risks.

Contacts and Further Information

• Investor Relations: Jessica Morris, [email protected], (862) 799-8599
• Media: Deborah Elson, [email protected] | Ray Jordan, [email protected]
• Company Website: www.tonixpharma.com

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially. Investors should review Tonix Pharmaceuticals’ filings with the SEC and consult their financial advisors before making investment decisions. The safety and efficacy of pipeline candidates have not been established unless otherwise noted. All information is accurate as of the date of publication.

View Tonix Pharmaceuticals Holding Corp. Historical chart here